Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2024 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Return on Invested Capital came in at 0.16% in Q1 2026, up 3.0% YoY from 0.16% in Q1 2025, and up 12.1% on a QoQ basis from 0.19% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2024 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 3 years of Return on Invested Capital data on file, last reported at 0.16% in Q1 2026.
- Quarterly Return on Invested Capital rose 3.0% year-over-year to 0.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.16% (up 3.0% YoY) and the FY2025 annual result came in at 0.74%, up 39.0% from the prior year.
- Return on Invested Capital advanced to 0.16% in Q1 2026, from 0.19% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.16% in Q1 2026 to a low of 90.6% in Q1 2024.
- A 3-year average of 10.34% and a median of 0.21% in 2025 frame the typical range for Return on Invested Capital.
- Annual changes were most pronounced in 2025 — Return on Invested Capital jumped 9040 bps — and 2026, when it increased 3 bps.
- Tracing RXRX's Return on Invested Capital over 3 years: stood at 0.23% in 2024, then climbed by 20 bps to 0.19% in 2025, then increased by 12 bps to 0.16% in 2026.
- The last three Return on Invested Capital figures came in at 0.16% (Q1 2026), 0.19% (Q4 2025), and 0.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -0.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.15% |
| Mar 31, 2026 | -0.16% |
| Dec 31, 2025 | -0.19% |
| Sep 30, 2025 | -0.21% |
| Jun 30, 2025 | -0.19% |
| Mar 31, 2025 | -0.20% |
| Dec 31, 2024 | -0.23% |
| Sep 30, 2024 | -0.32% |
| Jun 30, 2024 | -0.95% |
| Mar 31, 2024 | -90.60% |